Retatrutide Biologic Battle: The Story Gets Bigger
Summary
Host Dave Knapp analyzes the Eli Lilly vs. FDA lawsuit over retatrutide’s biologic classification, arguing it could redefine peptide regulations. He warns that if retatrutide is deemed a biologic, it may restrict compounding for future GLP-1 and GIP drugs, impacting patient access and pricing. The episode highlights upcoming Seventh Circuit oral arguments and their potential to reshape obesity medicine.
Topics discussed
Intro: Red Hat True Tide biologic fight impact
Welcome to On the Pen Podcast and host intro
Sponsor segment: VoaFit telehealth and obesity care
Overview of the retitutrude lawsuit and its importance
Lilly's BLA announcement and upcoming court arguments
Implications for compounding and future peptide drugs
FDA's 40 amino acid definition and judge's ruling
The 'analogous product' argument and remand details
Why Lilly fights: Market exclusivity and pricing power
Broader impact on pipeline drugs and insulin precedent
Future of obesity medicine and industry watch
Listener questions and podcast outro
Listen ad-free on Castria